Care Partners’ Perceptions of Amyloid-Targeting Therapy and Treat‑to‑Clearance for Alzheimer’s Disease in Japan: A Qualitative Study

Abstract Introduction Donanemab has been developed as an amyloid-targeting therapy (ATT) for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). In registration trials involving donanemab, a treat‑to‑clearance approach was used, in which patients discontinued ATT when...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sadao Katayama, Masashi Tsujimoto, Keisuke Suzuki, Kaname Ueda, Kanako Shimoura, Shintaro Suo, Naohisa Hatakeyama
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2025-11-01
Col·lecció:	Neurology and Therapy
Matèries:	Alzheimer’s disease Amyloid-targeting therapy Burden Care partners Dementia Dose cessation
Accés en línia:	https://doi.org/10.1007/s40120-025-00869-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!